368 related articles for article (PubMed ID: 25081573)
1. The risk of herpes zoster during biological therapy for psoriasis and other inflammatory conditions.
Adelzadeh L; Jourabchi N; Wu JJ
J Eur Acad Dermatol Venereol; 2014 Jul; 28(7):846-52. PubMed ID: 25081573
[TBL] [Abstract][Full Text] [Related]
2. Risk of herpes zoster with IL-17 inhibitor therapy for psoriasis and other inflammatory conditions.
Wu KK; Lee MP; Lee EB; Wu JJ
J Dermatolog Treat; 2020 Jun; 31(4):359-365. PubMed ID: 30900514
[No Abstract] [Full Text] [Related]
3. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
[TBL] [Abstract][Full Text] [Related]
4. A systematic review of herpes zoster incidence and consensus recommendations on vaccination in adult patients on systemic therapy for psoriasis or psoriatic arthritis: From the Medical Board of the National Psoriasis Foundation.
Baumrin E; Van Voorhees A; Garg A; Feldman SR; Merola JF
J Am Acad Dermatol; 2019 Jul; 81(1):102-110. PubMed ID: 30885757
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for herpes zoster in rheumatoid arthritis patients: the role of tumour necrosis factor-α inhibitors.
Segan J; Staples MP; March L; Lassere M; Chakravarty EF; Buchbinder R
Intern Med J; 2015 Mar; 45(3):310-8. PubMed ID: 25565419
[TBL] [Abstract][Full Text] [Related]
6. Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis.
Olivera PA; Lasa JS; Bonovas S; Danese S; Peyrin-Biroulet L
Gastroenterology; 2020 May; 158(6):1554-1573.e12. PubMed ID: 31926171
[TBL] [Abstract][Full Text] [Related]
7. Infliximab-induced psoriasis in treatment of Crohn's disease-associated ankylosing spondylitis: case report and review of 142 cases.
Famenini S; Wu JJ
J Drugs Dermatol; 2013 Aug; 12(8):939-43. PubMed ID: 23986169
[TBL] [Abstract][Full Text] [Related]
8. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings.
Bonafede M; Fox KM; Watson C; Princic N; Gandra SR
Adv Ther; 2012 Aug; 29(8):664-74. PubMed ID: 22886712
[TBL] [Abstract][Full Text] [Related]
9. Comparative Risk of Harm Associated With the Use of Targeted Immunomodulators: A Systematic Review.
Desai RJ; Thaler KJ; Mahlknecht P; Gartlehner G; McDonagh MS; Mesgarpour B; Mazinanian A; Glechner A; Gopalakrishnan C; Hansen RA
Arthritis Care Res (Hoboken); 2016 Aug; 68(8):1078-88. PubMed ID: 26663412
[TBL] [Abstract][Full Text] [Related]
10. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.
Gao X; Wendling D; Botteman MF; Carter JA; Rao S; Cifaldi M
J Med Econ; 2012; 15(6):1054-63. PubMed ID: 22563743
[TBL] [Abstract][Full Text] [Related]
11. The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study.
Zhang J; Delzell E; Xie F; Baddley JW; Spettell C; McMahan RM; Fernandes J; Chen L; Winthrop K; Curtis JR
Arthritis Res Ther; 2011; 13(5):R174. PubMed ID: 22024532
[TBL] [Abstract][Full Text] [Related]
12. New biologics for psoriasis and psoriatic arthritis.
Rozenblit M; Lebwohl M
Dermatol Ther; 2009; 22(1):56-60. PubMed ID: 19222517
[TBL] [Abstract][Full Text] [Related]
13. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
[TBL] [Abstract][Full Text] [Related]
14. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases.
Zhang J; Xie F; Delzell E; Chen L; Winthrop KL; Lewis JD; Saag KG; Baddley JW; Curtis JR
JAMA; 2012 Jul; 308(1):43-9. PubMed ID: 22760290
[TBL] [Abstract][Full Text] [Related]
15. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions.
Sfikakis PP
Curr Dir Autoimmun; 2010; 11():180-210. PubMed ID: 20173395
[TBL] [Abstract][Full Text] [Related]
16. Risk of herpes zoster associated with biological therapies for psoriasis and psoriatic arthritis: A systematic review and meta-analysis.
Zou A; Chen Y; Shi N; Ye Y
Medicine (Baltimore); 2021 Oct; 100(40):e27368. PubMed ID: 34622837
[TBL] [Abstract][Full Text] [Related]
17. [Tumour necrosis factor antagonists: infliximab, adalimumab and etanercept].
Breedveld FC
Ned Tijdschr Geneeskd; 2005 Oct; 149(41):2273-7. PubMed ID: 16240851
[TBL] [Abstract][Full Text] [Related]
18. Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series.
Cohen JD; Bournerias I; Buffard V; Paufler A; Chevalier X; Bagot M; Claudepierre P
J Rheumatol; 2007 Feb; 34(2):380-5. PubMed ID: 17013997
[TBL] [Abstract][Full Text] [Related]
19. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster.
Winthrop KL; Baddley JW; Chen L; Liu L; Grijalva CG; Delzell E; Beukelman T; Patkar NM; Xie F; Saag KG; Herrinton LJ; Solomon DH; Lewis JD; Curtis JR
JAMA; 2013 Mar; 309(9):887-95. PubMed ID: 23462785
[TBL] [Abstract][Full Text] [Related]
20. Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis.
Bonafede MM; Gandra SR; Watson C; Princic N; Fox KM
Adv Ther; 2012 Mar; 29(3):234-48. PubMed ID: 22411424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
